ArticleScientific reports2025
Expression profiling of KRAS and NOXA genes as prospective biomarkers in ovarian carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OC) is a leading cause of cancer deaths in women. Comprehensive molecular studies are required to understand OC pathogenesis. KRAS and NOXA genes are involved in tumorigenesis and disease progression. KRAS promotes tumor growth, while NOXA triggers the apoptotic signaling pathway.
methodsFifty-six ovarian cancer patients and twenty healthy controls were enrolled in the study. Gene expression profiling was performed utilizing the qRT-PCR assay. Then, the proteomic levels of KRAS and NOXA genes were assessed by the ELISA technique.
resultsThe results showed that KRAS gene expression was significantly increased in OC patients compared to controls (p < 0.0001). Additionally, KRAS overexpression was correlated significantly with more aggressive characteristics, including advanced stage, positive lymph invasion, and metastatic status (p = 0.04, 0.05, and 0.02, respectively). In contrast, NOXA expression was downregulated in OC patients compared to controls (p = 0.001), and this reduction was more pronounced in patients with more aggressive characteristics (p = 0.001, 0.01, 0.0008, 0.02, respectively). At the transcriptomic level, KRAS concentration was higher among the patient group (p = 0.03) and correlated with aggressive tumor features (p = < 0.0001, 0.001, and 0.03, respectively). Interestingly, no significant changes were detected in NOXA protein levels concerning ovarian cancer development and progression. These findings were further confirmed by receiver operating characteristic (ROC) curve analysis, validating the genetic and transcriptomic results.
conclusionThe differential expression of KRAS and NOXA genes holds promise as potential biomarkers for ovarian cancer development and progression. Specifically, KRAS transcriptomic levels serve as a reliable discriminator of ovarian cancer progression. In contrast, NOXA protein expression warrants further investigation to elucidate its role in the progression and pathophysiology of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.